Citadel Advisors
DSGN icon

Citadel Advisors’s Design Therapeutics DSGN Stock Holding History

Citadel Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Buy
+13,900
New +$173K ﹤0.01% 12058
2025
Q2 		– Sell
-4,000
Closed -$15.4K – 13072
2025
Q1 		$15.4K Sell
4,000
-600
-13% -$2.86K ﹤0.01% 13314
2024
Q4 		$28.4K Buy
4,600
+2,300
+100% +$13.3K ﹤0.01% 12922
2024
Q3 		$12.4K Buy
2,300
+1,200
+109% +$5.64K ﹤0.01% 13109
2024
Q2 		$3.69K Buy
1,100
+1,000
+1,000% +$3.9K ﹤0.01% 13561
2024
Q1 		$403 Sell
100
-2,500
-96% -$6.68K ﹤0.01% 14340
2023
Q4 		$6.89K Sell
2,600
-4,700
-64% -$10.8K ﹤0.01% 13327
2023
Q3 		$17.2K Buy
7,300
+6,100
+508% +$28.5K ﹤0.01% 12738
2023
Q2 		$7.56K Sell
1,200
-4,900
-80% -$30K ﹤0.01% 13364
2023
Q1 		$35.2K Sell
6,100
-159,500
-96% -$1.19M ﹤0.01% 12578
2022
Q4 		$1.7M Buy
165,600
+6,400
+4% +$86.7K ﹤0.01% 5779
2022
Q3 		$2.66M Buy
159,200
+27,000
+20% +$537K ﹤0.01% 5044
2022
Q2 		$1.85M Buy
+132,200
New +$1.79M ﹤0.01% 5688

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's DSGN Position: Q2 2026 in Review

Citadel Advisors reduced its Design Therapeutics (DSGN) stake by 65% in Q2 2026, selling an estimated $1.86M and leaving 81,971 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #7786.

Citadel Advisors first reported a position in DSGN in Q1 2021 and has held it in 22 quarters since. The position peaked at $75.8M in Q1 2021. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Citadel Advisors held 81,971 shares of Design Therapeutics worth $1.19M as of Q2 2026.
  • Citadel Advisors sold 149,542 Design Therapeutics shares in Q2 2026, an estimated $1.86M.
  • Design Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7786 holding.
  • Citadel Advisors first reported a position in Design Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Citadel Advisors's Design Therapeutics position peaked at $75.8M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.